66.43
Schlusskurs vom Vortag:
$65.31
Offen:
$65.15
24-Stunden-Volumen:
646.90K
Relative Volume:
1.56
Marktkapitalisierung:
$3.27B
Einnahmen:
$1.11B
Nettoeinkommen (Verlust:
$205.95M
KGV:
16.16
EPS:
4.11
Netto-Cashflow:
$254.64M
1W Leistung:
-11.62%
1M Leistung:
-13.16%
6M Leistung:
-22.47%
1J Leistung:
-1.26%
Prestige Consumer Healthcare Inc Stock (PBH) Company Profile
Firmenname
Prestige Consumer Healthcare Inc
Sektor
Telefon
(914) 524-6800
Adresse
660 WHITE PLAINS RD., TARRYTOWN, NY
Vergleichen Sie PBH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PBH
Prestige Consumer Healthcare Inc
|
66.43 | 3.14B | 1.11B | 205.95M | 254.64M | 4.11 |
![]()
ZTS
Zoetis Inc
|
152.44 | 66.38B | 9.39B | 2.61B | 2.22B | 5.81 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 46.20B | 29.98B | 958.27M | 5.31B | 0.2964 |
![]()
HLN
Haleon Plc Adr
|
9.69 | 42.99B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Prestige Consumer Healthcare Inc Stock (PBH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-12-09 | Herabstufung | Sidoti | Buy → Neutral |
2024-06-21 | Hochstufung | DA Davidson | Neutral → Buy |
2022-11-17 | Eingeleitet | Canaccord Genuity | Buy |
2022-05-10 | Hochstufung | Jefferies | Hold → Buy |
2022-05-09 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-08-07 | Herabstufung | DA Davidson | Buy → Neutral |
2020-06-29 | Hochstufung | Sidoti | Neutral → Buy |
2020-04-14 | Herabstufung | Jefferies | Buy → Hold |
2020-04-07 | Fortgesetzt | Sidoti | Neutral |
2020-03-26 | Hochstufung | Jefferies | Hold → Buy |
2020-03-24 | Eingeleitet | Oppenheimer | Perform |
2020-03-19 | Hochstufung | DA Davidson | Neutral → Buy |
2019-01-15 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2017-12-04 | Hochstufung | William Blair | Mkt Perform → Outperform |
2017-06-02 | Hochstufung | Jefferies | Underperform → Hold |
2017-05-22 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2016-12-27 | Bestätigt | B. Riley & Co. | Buy |
2016-11-17 | Eingeleitet | Gabelli & Co | Buy |
2016-08-12 | Hochstufung | Sidoti | Neutral → Buy |
2016-03-08 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
2016-02-05 | Eingeleitet | Piper Jaffray | Overweight |
2015-11-30 | Herabstufung | Jefferies | Hold → Underperform |
2014-04-28 | Bestätigt | B. Riley & Co. | Buy |
2014-04-28 | Bestätigt | Oppenheimer | Outperform |
2013-07-09 | Eingeleitet | B. Riley & Co. | Buy |
Alle ansehen
Prestige Consumer Healthcare Inc Aktie (PBH) Neueste Nachrichten
Prestige Consumer Healthcare (PBH) Trims Outlook as Sales Dip—Is the Acquisition Strategy Still on Track? - simplywall.st
Prestige Consumer Healthcare's Strategic Acquisition and Q1 Earnings: A Value Investment Case in a Resilient OTC Sector - AInvest
Prestige Consumer Healthcare Inc. (NYSE:PBH) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
Prestige Consumer Healthcare Acquires Pillar5 Pharma for Expansion - MSN
Prestige Consumer Healthcare Inc. (NYSE:PBH) Q1 2026 Earnings Call Transcript - Insider Monkey
Prestige Consumer Starting Clear Eyes Production With No Contract Partner ‘Out There To Tap Into’ - insights.citeline.com
Prestige Consumer Healthcare's Q1 2026: Key Contradictions in Clear Eyes Supply, Market Share, and Margin Outlook - AInvest
Prestige Consumer Healthcare stock hits 52-week low at 64.83 USD By Investing.com - Investing.com South Africa
Prestige Consumer Healthcare stock hits 52-week low at 64.83 USD - Investing.com Nigeria
Prestige Brands stock price target lowered to $100 at Canaccord on eye care supply issues - Investing.com Nigeria
Prestige Consumer Healthcare's Strategic Path to Recovery: Can Shareholders Capitalize on a Turnaround in Eye Care and Margin Expansion? - AInvest
Prestige Consumer Healthcare: Fiscal Q1 Earnings Snapshot - Manistee News Advocate
Prestige Consumer Healthcare: Strategic Acquisitions and Innovation Drive Long-Term Value Creation - AInvest
Prestige Consumer Healthcare outlines $1.1B-$1.115B FY26 revenue target amid Pillar5 acquisition and Clear Eyes supply recovery - MSN
Prestige Consumer Healthcare Q1 Earnings and Strategic Acquisition of Pillar5 Pharma - AInvest
Prestige Consumer Healthcare’s Q1 Earnings and Strategic Moves - TipRanks
Prestige Consumer Healthcare Q1 2026 Earnings Call Transcript - MarketBeat
Prestige Consumer Healthcare shares fall 10.14% intraday after missing Q1 revenue estimates and lowering fiscal 2026 outlook. - AInvest
Prestige Consumer Healthcare Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Prestige Consumer Healthcare Inc. Q1 Profit Decreases, Misses Estimates - Nasdaq
Prestige Consumer Healthcare (PBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Prestige Consumer Healthcare's Strategic Acquisition of Anjac SAS: A Catalyst for OTC Men's Health Dominance - AInvest
Prestige Consumer Healthcare Eyes Growth Despite Revenue Shortfall - Finimize
Prestige Consumer Healthcare on Aug 4, unit entered agreement with Anjac SASSEC filing - MarketScreener
Prestige Consumer Healthcare Q1 FY26 slides: Revenue drops on supply issues, margins improve - Investing.com Nigeria
Prestige Consumer Healthcare Q1 FY26 slides: Revenue drops on supply issues, margins improve By Investing.com - Investing.com South Africa
Prestige Consumer Healthcare (PBH) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Prestige Consumer Healthcare Q1 Revenue Falls 6.6% Amid Supply Constraints and Order Timing Shifts - AInvest
Prestige Consumer Healthcare's Strategic Acquisition of Pillar5 Pharma: A Masterstroke in Supply Chain Resilience and Competitive Edge - AInvest
Prestige Consumer Healthcare Reports Lower Q1 Earnings Than ExpectedNews and Statistics - IndexBox
Prestige (PBH) Q1 Revenue Falls 6.6% - The Globe and Mail
Prestige Consumer's Strategic Turnaround: Assessing Brand Resilience and M&A-Driven Growth in a High-Margin Sector - AInvest
Prestige Consumer Healthcare Inc. SEC 10-Q Report - TradingView
Prestige Consumer misses Q1 revenue estimates, to acquire Pillar5 Pharma - MarketScreener
Prestige Consumer Healthcare's Fiscal 2026 Q1 Earnings: A Strategic Masterclass in Brand Diversification and Operational Excellence - AInvest
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 First Quarter Results - GlobeNewswire
Prestige Healthcare Reports Mixed Q1 Results, Makes Strategic Eye Care Supplier Acquisition - Stock Titan
Stay Ahead of the Game With Prestige Consumer Healthcare (PBH) Q1 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Does Prestige Consumer Healthcare Inc. fit your quant trading modelPredictive AI Engine for Smart Investing - Newser
Using Python tools to backtest Prestige Consumer Healthcare Inc. strategiesImmediate Entry Point Prediction Strategy - Newser
Prestige Consumer Healthcare Inc. Flashes Rebound Signal in Oversold ConditionStrong Buy With Technical Confidence Supported - beatles.ru
Insights Ahead: Prestige Consumer's Quarterly Earnings - 富途牛牛
TheraTears® Unveils "It's a Science" Marketing Campaign - Yahoo Finance
Applying sector rotation models to Prestige Consumer Healthcare Inc.Chart-Based Entry Confirmation for Beginners - Newser
Why Prestige Consumer Healthcare Inc. stock attracts strong analyst attentionHigh Yield Signals with Entry Timing - Newser
Prestige Consumer Healthcare Inc.'s (NYSE:PBH) Price Is Out Of Tune With Earnings - simplywall.st
Applying Wyckoff theory to Prestige Consumer Healthcare Inc. stockWeekly High Conviction Trade Setup Analysis - Newser
Resistance Break Could Fuel Prestige Consumer Healthcare Inc. RallyOptimized Watchlist With Daily Adjustments Launched - metal.it
Finanzdaten der Prestige Consumer Healthcare Inc-Aktie (PBH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):